Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor

Malignant Solid Tumor Clinical Trial

Official title: Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor

Status Completed

Clinical Trial Summary

Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells.The hypothesis of the investigators is that immunotherapy strategy of infusion of iNKT cells may resist inflection and decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of treatment of tuberculosis with malignant solid tumor by infusing of iNKT cells.

Clinical Trial Description

Treatment of tuberculosis with malignant solid tumor is great unsolved challenge to the physicians. Efficacy of conventional treatment, such as surgery, radiotherapy and chemotherapy is limited. AS novel therapy, immunotherapy shows great prospects. Human iNKT cells can directly lysis tumor cells by a perforin-dependent mechanism,and intracellular granzyme B expression may also potentiate cell killing. Tumor cells expressing CD1d may be especially susceptible to direct NKT cell lysis. iNKT cells play important role in immune regulation by secreting various cytokines. Expansion method of iNKT cells in vitro is developed as published in the patent of the investigators. Infusion of iNKT cells has been proved safe in mice. In this clinical trial, the safety and efficacy of the immunotherapy of infusion of iNKT cells are assessed. ;

Related Conditions & MeSH terms

• Malignant Solid Tumor
• Neoplasms
• Tuberculosis

• NCT number: NCT03551795
• Study type: Interventional
• Source: Shanghai Public Health Clinical Center
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 1, 2018
• Completion date: March 31, 2022